Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbidopa-levodopa in Neovascular AMD Extension
NCT03197493Phase 2Completed
- Sponsor
- Robert W. Snyder
- Start
- Aug 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of levodopa and carbidopa in neovascular age-related macular degeneration (NVAMD), sponsored by Robert W. Snyder. Primary endpoint: Change in Best Corrected Visual Acuity by ETDRS Visual Scale Testing at 9 months. Started Aug 2017; status: completed.
02
Drugs
levodopacarbidopa
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03197493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197493.